Brussels, 27 April 2021 – EuropaBio is pleased to announce that the Lithuanian
Biotechnology Association (LBTA) has joined the National Association Council (NAC).
The LBTA has 29 industry and academic members and has a focus on life sciences, health
technologies and bioeconomics. It has the mission to build on an existing established
economic foundation from biotechnology, with national activities including vaccine manufacture. As part of the EuropaBio NAC, LBTA will feature in the May 10 NAC Summit
‘Building on biotechnology: From vaccines to economic growth for Europe’, discussing how
Europe must build from the advances in policy, funding and collaboration during Covid, to
enable continued economic growth from biotech.
EuropaBio Director-General Dr. Claire Skentelbery says “LBTA really demonstrates how all
European countries play a critical role in delivering biotechnology as an economic and
societal contributor. We are delighted to bring their expertise into the National Associations
Council and look forward to the NAC Summit on May 10”.
Agne Vaitkeviciene, Executive Director of the LBTA added ”Lithuania is pioneering in
genome editing technologies [CRIPSR-CAs9] that has immense potential in the DNA/RNA
vaccine development. In addition, we have immense scientific expertise in the field related
to emerging non-viral vaccine technology. Faster recovery from pandemics calls for
collaboration and Lithuania is ready to share its biotech potential and to contribute to
production and development of life-saving biotech products.
